NeuPharma (Worldwide License to CK-101) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

NeuPharma (Worldwide License to CK-101) General Information

Description

A kinase inhibitor license in the United States. The epidermal growth factor receptor (EGFR) inhibitor provides treatment to patients with EGFR mutation-positive non-small cell lung cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Acquirer
Checkpoint Therapeutics
Corporate Office
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuPharma (Worldwide License to CK-101) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NeuPharma (Worldwide License to CK-101)‘s full profile, request access.

Request a free trial

NeuPharma (Worldwide License to CK-101) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NeuPharma (Worldwide License to CK-101)‘s full profile, request access.

Request a free trial

NeuPharma (Worldwide License to CK-101) FAQs

  • Where is NeuPharma (Worldwide License to CK-101) headquartered?

    NeuPharma (Worldwide License to CK-101) is headquartered in .

  • What industry is NeuPharma (Worldwide License to CK-101) in?

    NeuPharma (Worldwide License to CK-101)’s primary industry is Buildings and Property.

  • Is NeuPharma (Worldwide License to CK-101) a private or public company?

    NeuPharma (Worldwide License to CK-101) is a Private company.

  • What is NeuPharma (Worldwide License to CK-101)’s current revenue?

    The current revenue for NeuPharma (Worldwide License to CK-101) is .

  • Who are NeuPharma (Worldwide License to CK-101)’s investors?

    NeuPharma has invested in NeuPharma (Worldwide License to CK-101).

  • Who acquired NeuPharma (Worldwide License to CK-101)?

    NeuPharma (Worldwide License to CK-101) was acquired by Checkpoint Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »